United States: Health Care Policy Newsletter - 21 May 2018

Foley & Lardner LLP's ("Foley") Bipartisan Public Policy Team is pleased to share our "Public Policy Weekly Health Care Newsletter" in which we compile the latest health care policy news and legislation.
*Please note that we publish this newsletter only when Congress is in session.

Health Care Policy Review (May 14-18, 2018)


Legislation and Committee Activity

House Opioid Vote – Rep. Greg Walden (R-OR), said Thursday he has fulfilled his commitment to advance legislation to combat the opioid crisis to the House by Memorial Day. The House Energy and Commerce Committee, where Walden serves as Chairman, advanced 32 more bills Thursday — for a total of 57 measures sent to the full House to address the opioid crisis in Oregon and across the country. Read More

A Sustainable Solution To The Evolving Opioid Crisis: Revitalizing The Office Of National Drug Control Policy Hearing – On Thursday, the House Oversight Committee held a hearing to discuss the revitalization of the Office of National Drug Control Policy to address the nationwide opioid epidemic. Read More

Ways & Means Opioid Markup – On Wednesday, the House Ways and Means Committee held a markup and today advanced seven bipartisan bills aimed at addressing the opioid crisis. Read More

On Tuesday, Reps. Mike Bishop (R-MI) and Bill Pascrell (D-NJ) introduced the Securing the International Mail Against Opioids Act of 2018 (H.R. 5788) which will impose new requirements on the Postal Service and Customs and Border Protection (CBP) to address the opioids epidemic by securing the international mail. Read More

On Thursday, Sens. Shelley Moore Capito (R-WV) and Catherine Cortez Masto (D-NV) introduced the Opioid Addiction Recovery Fraud Prevention Act of 2018 (S.2842) which would prohibit the marketing of "bogus" opioid treatment programs or products. Read More

On Monday, Sen. John Thune (R-SD) introduced the Fighting Opioid Abuse in Transportation Act (S. 2848) which would improve Department of Transportation controlled substances and alcohol testing. Read More

The Hill: GOP chairman plans hearings on Trump drug pricing proposals – House Ways and Means Committee Chairman Kevin Brady (R-Texas) said Tuesday that he plans to conduct hearings on some of President Trump's new proposals to bring down drug prices. Brady said it is too early to tell if the committee will move legislation on the issue, but said he wanted to consider the ideas. Read More

The Hill: Overnight Health Care —ObamaCare premium wars are back – But they're looking different than in years past. During the Obama administration, Republicans railed against Obamacare's premium hikes while pledging to repeal and replace the law. But that repeal push ended in failure last year, Democrats say the political winds have shifted in their favor. Read More

NIH Director Testifies at Appropriations Hearing – On Thursday, NIH Director Francis Collins testified before the Senate Appropriations Labor-HHS-Education Subcommittee on the proposed 2019 fiscal budget for the National institutes of Health. Read More

Modern Healthcare: Senate committee turns 340B spotlight on drugmakers – Lawmakers turned their sharp scrutiny of the 340B program on drugmakers Tuesday, questioning why states and providers don't know the ceiling prices within the drug discount program. Read More

Senator Murray Highlights Importance of Funding Health Research, Criticizes Trump Proposal to Undermine Investments in Bipartisan Budget Deal – On Wednesday, U.S. Senator Patty Murray (D-WA), top Democrat on the Labor, Health and Human Services, Education, and Related Agencies Appropriations Subcommittee (LHHS), highlighted the importance of continuing to invest in groundbreaking, lifesaving medical research during a committee hearing on medical research funding. Read More

Politico: McConnell threatens to kill August recess – Senate Majority Leader Mitch McConnell is seriously considering scrapping some or all of the August recess this year, according to senators and aides. The GOP leader told Republican chairmen on Wednesday that he would speak to Senate Minority Leader Chuck Schumer (D-N.Y.) about whether Democrats are willing to cooperate at all on spending bills and President Donald Trump's nominations in order to avoid scuttling this year's four-week break. Read More

Senators Send Letter to Request CMS Administrator at Hearing – On Monday, the Senate Homeland Security and Governmental Affairs Committee sent a letter to CMS Administration, Seema Verma, asking her to testify at a hearing in mid-June and noting if Verma does not confirm her appearance, the panel may be forced to seek alternative means to compel her to testify. Read More



Health Information Technology: Certification and Interoperability Enhancements – Last week, the federal government released its Spring unified agenda, included was a proposed rule to update the ONC Health IT Certification Program (Program) by implementing certain provisions of the 21st Century Cures Act. Thisincludes conditions and maintenance of certification requirements for health information technology (IT) developers, the voluntary certification of health IT for use by pediatric healthcare providers, health information network voluntary attestation to the adoption of a trusted exchange framework and common agreement in support of network-to-network exchange, and reasonable and necessary activities that do not constitute information blocking. The rulemaking would also modify the Program through other complementary means to advance health IT certification and interoperability. Read More

HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs – Notice of the Department of Health and Human Services announces a blueprint to improve the affordability and accessibility of prescription drugs and a request for information on proposed policies. The agency requests information on the impacts of federal drug rebate programs and Affordable Care Act taxes and rebates on competition. Comments on any other policies that may impact drug list prices, net prices, and out-of-pocket drug spending are also requested. Comments are due July 16, 2018. Read More

NPR: Trump Administration's 3 Biggest Ideas For Lowering Drug Prices – Azar was making the point that in the area of drug prices, the head of HHS — which runs the Medicare and Medicaid programs and buys about $130 billion in prescription drugs each year — can make a lot of changes in the pharmaceutical market. And he doesn't need congressional approval to do it. Read More

Bloomberg: Trump Administration to Propose New Curbs on Abortion – The Trump administration will propose new rules to bar Planned Parenthood and other health-care providers from performing abortions at facilities that receive federal family planning funds, an administration official said on Thursday night. Read More


The Hill: Overnight Health Care —Trump official won't OK lifetime limits on Medicaid – Verma once again made it clear that the Trump administration isn't giving conservative states a blank check for changes to Medicaid. During an event hosted by The Washington Post, Verma said the administration will not approve any requests by states to impose lifetime limits. Read More

Modern Healthcare: Medicaid payment for opioid treatment embroiled in politics over loosening restrictions – In Cincinnati, wait times for opioid addicts seeking residential treatment have dropped as the city's providers are banding together to manage the barrage of cases across different settings. In January, Mercy Health partnered with 10 outpatient treatment centers. The hospital offers short-term detox stays for patients, then the clinics take over and manage the long-term treatment, nearly on demand. After they have stabilized, patients can decide whether they want residential treatment or outpatient care. Read More

Pharmacy Gag Clauses – On Thursday, CMS sent a letter to plans that participate in Medicare Part D advising them to drop "gag clauses" that some health plans and pharmacy benefit managers include in their contracts with pharmacies. Read More


FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults – The U.S. Food and Drug Administration today approved Lucemyra (lofexidine hydrochloride) for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. While Lucemyra may lessen the severity of withdrawal symptoms, it may not completely prevent them and is only approved for treatment for up to 14 days. Lucemyra is not a treatment for opioid use disorder (OUD), but can be used as part of a broader, long-term treatment plan for managing OUD. Read More

Modern Healthcare: FDA calls out drugmakers to promote greater generic competition – The U.S. Food and Drug Administration on Thursday called out 39 drugmakers for potentially blocking access to their drug samples in an effort to delay generic competition. Read More

Veteran Affairs

Nextgov: VA Signs $10 Billion Health Records Contract With Cerner – The Veterans Affairs Department inked a 10-year, $10 billion contract Thursday with Cerner Corp. to adopt the same commercial electronic health records system as the Pentagon. Read More


The Hill: Court rules Dem states can intervene in ObamaCare lawsuit – A federal judge granted a request from states looking to defend ObamaCare in a lawsuit filed in Texas. California Attorney General Xavier Becerra, and 16 other state attorneys general in Democratic states were granted the right to intervene in the lawsuit that seeks to dismantle the Affordable Care Act (ACA). Read More

Vermont Drug Importation Program Will Need Federal Approval – Vermont is attempting to create a first-in-the-nation program to allow the wholesale importation of prescription drugs from Canada, but first the state needs approval from skeptical White House officials. Republican Gov. Phil Scott signed a bill Wednesday that passed with overwhelming support from Vermont's three political parties. Read More

LePage administration responds to Medicaid lawsuit, blames Legislature for not funding expansion – The DHHS says in a court filing that without the funds it 'lacks legal authority' to spend on expansion, but the plaintiffs point to unexpended funds in the state's Medicaid account and say the voter-approved law is being violated. Read More

SF Gate: Covered California premiums projected to rise 11 percent in 2019 – The cost of health insurance continues to climb in California. Estimates released Thursday by Covered California, the state insurance marketplace, project that premiums in the individual market will rise 11 percent next year, while enrollment in the exchange — which is larger than any other state's — will drop 12 percent. Read More


NY Times: 3 Key Takeaways From Tuesday Night – Four states held primary elections on Tuesday, but one loomed the largest by far: Pennsylvania. In a state that has emerged as one of the most important battlegrounds of 2018, Democrats settled a cluster of chaotic nomination fights — and Republicans, despite being on the defensive, sent a signal of strong support for President Trump. Read More

On May 22, Arkansas, Georgia, Kentucky, and Texas will head to the polls. Read More


Our attorneys at Foley pride themselves on having a first-hand understanding of health care's business and legal challenges. Health Care Law Today is your go-to resource for information and perspectives on the latest news and developments in health care law and how it relates to and impacts the industry and those with related business interests. For some of the blog's top stories – Read More https://www.healthcarelawtoday.com/


The House and Senate are both in session next week.

Washington Examiner: House to vote on 'right to try' bill next week – The House will vote this week on the Right to Try Act (S. 204), which would give terminally ill patients access to possibly life-saving experimental medicine. House Majority Leader Kevin McCarthy (R-CA) made the announcement Thursday morning, which comes nearly two months after the House passed a different version of right to try, but could not get it through the Senate. The Senate unanimously passed its version of the bill in August. That version was introduced by Sen. Ron Johnson (R-WI) and Sen. Joe Donnelly (D-IN) and is the one the House is now poised to vote on. Read More

On May 22, Senate Health, Education, Labor and Pensions (HELP) Committee will hold a hearing on the Healthcare Workforce Issues. Read More

On May 22, Senate Commerce, Science and Transportation Committee plans to mark up, the Fighting Opioid Abuse in Transportation Act (S. 2848). Read More

On May 22, Senate Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies will hold a markup on Agriculture-FDA-Rural Development Appropriations. Read More

On May 23, Senate Appropriations Subcommittee on Interior, Environment and Related Agencies will hold a hearing on Indian Health Service Budget. Read More

On May 23, Senate HELP Committee will hold a markup on the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S.2852). Read More

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions